Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc.
- Market cap
- $304.61M
Your view on RLMD
Overview
What the company does, where it operates, and who runs it.
About Relmada Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sergio Traversa
- Headquarters
- 2222 Ponce de Leon Boulevard, Coral Gables, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sergio Traversa
- Headquarters
- 2222 Ponce de Leon Boulevard, Coral Gables, FL, US
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders.
Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.
The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Relmada Therapeutics, Inc.. Starting points for Relmada Therapeutics, Inc.: EPS -$0.58, beta 0.45 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Relmada Therapeutics, Inc.. Trailing twelve-month EPS for Relmada Therapeutics, Inc. stands at -$0.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$9.75
average of 4 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy5
- Hold2
- Sell1
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | −$0.13 | −$0.15 | −$0.56 | −$0.75 |
| Low estimate | −$0.16 | −$0.17 | −$0.56 | −$0.94 |
| High estimate | −$0.09 | −$0.11 | −$0.55 | −$0.55 |
| No. of analysts | 3 | 2 | 2 | 2 |
| Year-ago EPS | −$0.271 | −$0.22 | −$1.451 | — |
| Growth | — | +34.1% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $10.00M | $32.45M |
| Low estimate | $0.00 | $0.00 | $10.00M | $32.45M |
| High estimate | $0.00 | $0.00 | $10.00M | $32.45M |
| No. of analysts | 0 | 0 | 3 | 4 |
| Year-ago revenue | $0.00 | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Relmada Therapeutics, Inc.. Relmada Therapeutics, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ACETAdicet Bio, Inc. | Healthcare | Biotechnology | $23.4M | ||
| ACRVAcrivon Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | $66.9M | ||
| CBUSCibus, Inc. | Healthcare | Biotechnology | $104.7M | ||
| FBIOFortress Biotech, Inc. | Healthcare | Biotechnology | $63.0M | ||
| IMUXImmunic, Inc. | Healthcare | Biotechnology | $102.6M | ||
| LITSLite Strategy, Inc. | Healthcare | Biotechnology | $24.1M | ||
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | Biotechnology | $65.1M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| VRDNViridian Therapeutics, Inc. | Healthcare | NASDAQ | $3.4B | ||
| VRPXVirpax Pharmaceuticals, Inc. | Healthcare | NASDAQ | $26,093 | ||
| VRTXVertex Pharmaceuticals Incorporated | Healthcare | NASDAQ | $136.0B | ||
| VRXAVeraxa Biotech Holding AG | Healthcare | NASDAQ | $145.7M | ||
| VRXAWVeraxa Biotech AG | Healthcare | NASDAQ | $579,370 | ||
| SPRCSciSparc Ltd. | Healthcare | NASDAQ | $156,921 | ||
| SPROSpero Therapeutics, Inc. | Healthcare | NASDAQ | $50.9M | ||
| SPRYARS Pharmaceuticals, Inc. | Healthcare | NASDAQ | $370.9M | ||
| SPTXSeaport Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $980.1M | ||
| SQZBSQZ Biotechnologies Company | Healthcare | OTC | $707,787 | ||
| SRBCFSirona Biochem Corp. | Healthcare | OTC | $1.6M | ||
| SRNESorrento Therapeutics, Inc. | Healthcare | OTC | $2.6M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.01% | |
| XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged) | $627M in assets | 0.01% | |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $516M in assets | 0.76% | |
| BBCVirtus LifeSci Biotech Clinical Trials ETF | $32M in assets | 0.39% | |
| SBIOALPS Medical Breakthroughs ETF | $187M in assets | 0.23% | |
| IWCiShares Micro-Cap ETF | $1.2B in assets | 0.08% | |
| VFMOVanguard U.S. Momentum Factor ETF | $1.9B in assets | 0.05% | |
Largest holders first, then the funds most concentrated in RLMD.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Relmada Therapeutics, Inc., and how their positions are changing. At a $304.6M market value, institutional positions materially move Relmada Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Relmada Therapeutics, Inc. executives and directors. Shares of Relmada Therapeutics, Inc. have traded between $0.24 and $4.38 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Relmada Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Relmada Therapeutics, Inc.. Coverage tracks Relmada Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Relmada Therapeutics, Inc.